SCNX · Scienture Holdings, Inc.
The latest filing states the doubt was alleviated.
“While these conditions initially indicated substantial doubt about the Company's ability to continue as a going concern, management believes that its plans described above alleviate that doubt for at least one year after the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Arbli™ wholesale unit sales | 74% | third quarter ended September 30, 2026 | — |
| Adjusted EBITDA non-GAAP | -$2,134,705 | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net loss -$2,822,371
+$461,571 Depreciation and amortization
+$269,785 Interest expense
-$147,147 Other non-operating expenses (income)
+$103,457 Stock based compensation (non-cash)
= Adjusted EBITDA -$2,134,705
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Pharmaceutical Retailers — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SCNX
this stock
Scienture Holdings, Inc.
|
$4.80M | — | +30.7% | — | 3.2% |
|
RTEZ
REST EZ Inc.
|
$4.20B | — | -100.0% | — | 0.0% |
|
HITI
High Tide Inc.
|
$233.55M | -1.1% | — | — | 0.8% |
|
BHIC
BioScience Health Innovations, Inc.
|
$79.68M | — | +208.3% | — | 0.0% |
|
SHFH
Scientist Home Future Health Ltd
|
$40.32M | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 19, 2026
- This year
- 14
Scienture Holdings reported preliminary Q3 2026 revenue of approximately $1.22 million, up 256% from approximately $344,000 in Q2 2026, driven by Arbli 74% wholesale unit sales growth and REZENOPY launch. The company regained Nasdaq compliance with the $1.00 minimum bid price requirement.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SCNX | -25.3% | -61.7% | -69.5% | -55.1% | -77.1% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -23.8% | -60.8% | -77.2% | -55.6% | -89.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.